Business
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
SOUTH SAN FRANCISCO, Calif. & BANNOCKBURN, Ill., August 07, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it has formed a strategic relationship with Option Care Health, Inc. (Nasdaq: OPCH), the nation’s largest independent provider of home and ambulatory infusion services, to support the commercial development and efficient launch of Quince’s
About this update from Option Care Health, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/d6be5abf74562a90f0558bf35af6ef29"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZIuJLg0sHY44JNN5rxWjNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d6be5abf74562a90f0558bf35af6ef29","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NWm102P9Vu3abERlMW0.FA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d6be5abf74562a90f0558bf35af6ef29","width":1121,"height":442}},"lazy":false},{"type":"text","content":"Provides access to broad-reaching nationwide network of specialty pharmacy and ambulatory infusion suites across the U.S.","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif. & BANNOCKBURN, Ill., August 07, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it has formed a strategic relationship with Option Care Health, Inc. (Nasdaq: OPCH), the nation’s largest independent provider of home and ambulatory infusion services, to support the commercial development and efficient launch of Quince’s lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the U.S., assuming positive study results and subsequent regulatory approval.","length":664,"tagName":"p"},{"type":"text","content":"The strategic relationship will leverage Option Care Health’s robust network of specialty pharmacies and ambulatory infusion suites to provide for the administration of eDSP in an effective and efficient way while delivering this innovative treatment to patients. With a national footprint of more than 90 full-service pharmacies and 180-plus ambulatory infusion suites located across the U.S., Option Care Health is well positioned to dramatically enhance Quince’s ability to provide patients with Ataxia-Telangiectasia (A-T) access to eDSP treatment, including greater geographic flexibility to match patient locations and eDSP administration needs, an improved and standardized patient journey with higher control...